New xenograft-based dressing might hit the market by summer

02/21/2012 | MedCityNews.com

Harbor Medtech is preparing to submit a request that the FDA approve its NeuvoCell wound dressing based on porcine tissue. NeuvoCell will be less expensive than similar products already on the market, requires applications only once or twice instead of every seven to 10 days, and will be appropriate to treat diabetic foot ulcers, pressure ulcers and burns, founder Jerry Mezger said.

View Full Article in:

MedCityNews.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Accreditation
Meridian Health Plan
Detroit, MI
Stop Loss Sales Executive, (Southern Region)
Indigo Insurance Services
Multiple Locations, SL_Multiple Locations
Regulatory Senior Managing/Principal Engineer/Scientist
Exponent
Menlo Park, CA
Chief Executive Officer
Center for Improving Value in Healthcare
Denver, CO
Quality Program Manager II, State Programs
Tufts Health Plan
Watertown, MA